产品
编 号：F495756
分子式：C34H59N9O12
分子量：785.89
分子式：C34H59N9O12
分子量：785.89
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 881851-50-9
产品详情
生物活性：
Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection.
体内研究：
Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice.Animal Model:HLA-HCD4/DQ8 double transgenic mice
Dosage:250 μg
Administration:Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
体外研究：
Larazotide acetate(1-100 μM; 5 d) affects Vero cell growth.Larazotide acetate(1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively.Larazotide acetate(1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells.Larazotide acetate(12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells.
Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection.
体内研究：
Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice.Animal Model:HLA-HCD4/DQ8 double transgenic mice
Dosage:250 μg
Administration:Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
体外研究：
Larazotide acetate(1-100 μM; 5 d) affects Vero cell growth.Larazotide acetate(1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively.Larazotide acetate(1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells.Larazotide acetate(12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备